Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

New York University researchers say a simple, gene-based blood test has shown to be highly accurate in predicting whether ...

Levies on Americans’ daily prescriptions and other medicines could raise costs, spur rationing and lead to shortages of ...

At the same time, drugmakers have come to rely on the U.S. market for the bulk of their revenue. In 2022, the U.S. accounted ...

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

A three-judge panel wrestled Thursday with Novartis AG’s challenge against the FDA over its approval of a generic version of ...

Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis knee pain. The Big Pharma company discontinued the study testing intra ...

Novartis NVS shares ended the last trading session 4% higher at $107.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...